

ersonal use only



FY26 Results Presentation

19 August 2026

Disclaimer



The information contained in this document ("Document") has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as "Alcidion" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Alcidion periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein. The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast.

The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect

any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Alcidion's business and markets. Such information is generally based on independent market and industry data or research. The Alcidion has not independently verified, and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Financial data

All financial amounts contained in this presentation are expressed in Australian dollars (unless otherwise stated). Any discrepancies between totals and sums of components in tables, figures and body content contained in this presentation are due to rounding. Tables, figures and body content contained in this presentation have not been amended by ALC to correct immaterial summation differences that may arise from this rounding convention.

Investors should also be aware that certain financial data included in this presentation including underlying NPAT and underlying EBIT/EBITDA and measures described as "pro-forma", are "non-IFRS financial information" under ASIC regulatory Guide 230 (disclosing non-IFRS financial information). The non-IFRS financial information financial measures do not have a standardised meaning prescribed by Australian International Reporting Standards (AIFRS) and, therefore, may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other measures determined in accordance with AIFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial measures included in this presentation.

01.

Snapshot &
Miya Precision
Platform



Investment Highlights



Large Addressable Market

- ▶ Global patient flow market growing at 18% CAGR and expected to hit US\$10B by 2034
- ▶ Structural tailwinds given digitisation of healthcare to safely meet rising demands of clinicians, administrators and patient safety
- ▶ New market entry into Canada and Middle East provides greenfield expansion

Attractive Financial Profile

- ▶ \$51.6M FY26 revenue, up 27% pcp
- ▶ ARR as at 30 June 2026 of \$38.3M
- ▶ FY26 Underlying EBITDA of \$6.8M
- ▶ ~100% operating cashflow conversion

Marquee Customers

- ▶ \$50M over 10 years with North Cumbria NHS to deliver new EPR
- ▶ \$40M+ with Leidos to assist Australian Defence Force (ADF) with health record
- ▶ \$35M over 7 years with UH Sussex NHS to deliver new EPR

Mission Critical Platform

- ▶ Cloud native platform improving hospital efficiencies (bed blockage) and clinical decision-making
- ▶ Provides interoperable System of Record enabling AI workflows and engagement
- ▶ Virtual care offering addressing models of care outside hospital setting

Long-term Contracts

- ▶ Long-term customer contracts (typically 5-10 years) with ongoing options for renewal
- ▶ Critical nature of software results in minimal churn
- ▶ Enterprise healthcare organisations (NHS Trusts, State health, private health)

Accelerated Momentum

- ▶ Referenceability combined with increasing market share supports pipeline conversion
- ▶ Governments committed to their pursuit of modernising system with significant funding being allocated

Company Overview



A leading global health informatics platform modernising legacy health systems at scale



Global health informatics platform enhancing and replacing outdated, manual and legacy systems to meet modern day demands in healthcare.



Flagship product, **Miya Precision** – delivering real-time, intuitive, clinical decision support, AI enablement layer for safer delivery of care, clinical workflow and much needed operational efficiencies.



Solving **systemic problems in healthcare** delivery – fragmented data, clinician workload pressures, operational inefficiencies and lack of system-wide operational insight.

100+

Healthcare Clients
transforming healthcare with Alcidion across more than 50,000 beds

130k+

Active Users
across Miya Precision and Smartpage

1B+

Observations Recorded
electronically at the point of care

25M+

Alerts Generated
to highlight patient deterioration

12%

Decrease in LoS
independently validated benefits

\$1B+


Annual Impact
on the global healthcare economy

Strong Global Footprint

Growing global operations diversified across attractive target markets



ersonal use only



Global footprint across the UK, Australia and NZ.



100+ clinical system implementations.



A platform approach to modernising healthcare assets and transforming the clinician experience.

 Prospective Territories

Alcidion: Solving critical healthcare challenges



Admin / clinical staff lack real-time visibility on bed availability & patient journey status



Long-term patient medical history is incomplete, missing context, or not transferring care settings



Disparate systems don't interoperate; challenges managing patient info, bed management, meds, etc



Hospital executives lack real-time visibility of hospital-wide operations (i.e. potential bottlenecks)



Ability to safely monitor patients at home vs. in hospital (better outcomes)

Core problems we solve

Our Platform



MIYA PRECISION
BY ALCIDION



Patient Flow



Integrated Care Record



Modern, Modular EPR



Operations Centre



Virtual Care & RPM

Our Solutions

Example Customers



Health
Northern Adelaide
Local Health Network

AlfredHealth



NHS
North Cumbria
Integrated Care
NHS Foundation Trust

NHS
South Tees Hospitals
NHS Foundation Trust

Hume
Rural Health Alliance

NSW
GOVERNMENT
Health
Sydney
Local Health District

Gold Coast Health
always care

What is Miya Precision?

An unrivalled clinical and administration platform



Designed for AI

Miya Precision allows for AI enabling data consolidation to deliver insights to clinicians, whilst maintaining patient safety

Digital Clinical Workflow

Miya Precision enables clinicians to fully coordinate patient care, tasks, alerts and communication digitally



Integrate and Liberate Data

Maximise the value of exiting Health IT investments



Operate in Real-Time

Systemwide transparency is available in real-time, showing bed availability, blockages, and critical events



Intuitive User Interfaces

World leading visualisation and user experience

Full Suite
EPR/EMR

Patient
Administration

Patient
Flow

Clinical Decision
Support

Clinical
Communications

Electronic
Observations

Data
Interoperability

System Wide
Analytics

02.

FY26 Highlights

EXECUTIVE SUMMARY

FY26 – Financial Highlights

Growth across all key financial metrics



Revenue

\$51.6M

Up **27%** on pcp¹

Driven by several contract wins and expansions

ARR² (as at 30 Jun-26)

\$38.3M

Up **34%** on pcp

Incl. ARR of \$3.6M from Kyra products acquisition

Increasing recurring revenue base underpinned by long-term contracts

New & renewal TCV

\$78.5M

Up **6%** on pcp

\$62.2m (or 79%) represents new contract sales

EBITDA³

\$6.2M

Up **28%** on pcp

Underlying EBITDA of \$6.8M (up 34% on pcp)

Positive operating cashflow

\$6.8M

Up **19%** on pcp

\$20.6M cash, no debt as at 30 June 2026

1. Comparisons are to prior corresponding period (FY25)

2. Annual Recurring Revenue defined as the value of Support & Maintenance (S&M), hosting and/or license revenue expected to be billed over the next 12 months. This does not include multi-year capital licenses paid during the year which will reoccur again upon a future contract renewal. ARR is a measure of the future annualised revenue as at a point in time.

3. EBITDA: includes share-based payments (\$199k) and one-off restructure costs (\$236k) and M&A transaction costs (\$175k).

FY26 – Operational Highlights

Continuing sales momentum + strategic patient flow acquisition



New, Expanded & Renewal Contracts

- › Significant new and expanded contracts:
 - › Sept-25: North Cumbria NHS Trust² (UK): Expanded partnership with Mizaic (EDM¹ solution) and non-clinical comms (in Q3)
 - › Nov-25: Leidos Australia (AUS): Expansion to include additional Miya Precision and Medications management capability
 - › Mar-26: Gold Coast Health (AUS): 5-year contract to deliver end-to-end remote patient monitoring (virtual care)
 - › May-26: UH Sussex (UK): 7-year contract to deliver comprehensive Electronic Patient Record (EPR) solution
- › Significant extended (renewal) contracts:
 - › Q1 FY26: Bolton NHS (UK): 3-year renewal for Miya Observations & Assessments module (Patientrack)
 - › Q2 FY26: NHS Lanarkshire (UK): 3-year renewal for Miya Observations & Assessments module (Patientrack)
 - › Q3 FY26: Renewal of several PCS (PAS) customer for multi-year periods including Harrogate and Northumbria
 - › Q4 FY26: Western Health (Aust): 4-year renewal for Patient Flow capability (5th contract renewal in past 20 years)

Kyra Flow Products Acquisition

- › On 29 June 2026, completed acquisition of the Kyra flow products from Telstra Health
- › Strategic acquisition adding 33 new customers (31 new) and consolidating leadership position in Australian patient flow market
- › Immediately earnings accretive with implied upfront EBITDA multiple of ~2.7x (FY26 f/cast EBITDA of \$1.1M)

¹. EDM = Electronic document management

03.

Financial Results

FY26 RESULTS

Profit & Loss



Strong revenue growth driving improved operating leverage

Profit & loss (A\$000)	FY25	FY26	% Change
Recurring revenue:			
Product - M&S ¹ + annual licences	25,968	31,885	23%
Product - Capital licences	8,440	9,836	17%
Non-recurring revenue:			
Product Implementation & services	6,378	9,920	56%
Total revenue	40,786	51,641	27%
Direct costs	(4,797)	(10,182)	112%
Gross profit	35,989	41,459	15%
<i>Gross profit %</i>	88.2%	80.3%	
Salaries & wages	(26,212)	(27,094)	3%
Other operating expenses	(5,614)	(6,612)	18%
Foreign exchange gain (loss)	935	(927)	NM
Underlying EBITDA	5,098	6,826	34%
EBITDA	4,846	6,216	28%
EBIT	253	1,214	380%
NPAT	1,654	2,285	38%

- › 27% increase in revenue
 - › 21% increase in recurring revenue driven by full year impact of new customer wins in FY25 + North Cumbria and Leidos (ADF) expansions and License fee from UH Sussex
 - › 56% growth in implementation revenue, driven primarily by major deployments at Hywel Dda, North Cumbria and Leidos
- › Gross profit of \$41.5M an increase of 15% with gross % margin decrease on prior year
 - › Resulting from resale of third-party partner products where ALC acts as contract prime – notably Mizaic (North Cumbria), Better (UH Sussex)
 - › Margin impact not expected to continue with FY27 forecast gross margins to return to mid 80%’s
- › Modest salaries & wages growth of 3%, with staffing levels broadly consistent throughout FY26; ending with headcount of ~140
- › \$5.0M D&A incl. \$4.0M amortisation on acquired intangibles (ie non-cash)

1. M&S: Maintenance & Support
2. NM: Not meaningful


Revenue Dashboard




Sustainable growth underpinned by long-term, contracted and high-quality recurring revenue

Personal use only


H1 vs H2
Revenue
Split (\$M)




Geographical
Split (%)



Revenue
Category
Breakdown
(\$M)




% Recurring
(product) of
Total Revenue



Our revenue model



Sustainable growth underpinned by long-term, contracted and high-quality recurring revenue



Balance Sheet



Significant balance sheet flexibility to pursue growth opportunities

Balance sheet (\$000)	30 Jun 25	30 Jun 26
Cash & cash equivalents	17,697	20,642
Trade & other receivables	3,680	6,060
Other assets	2,310	3,021
Current assets	23,687	29,723
Plant & equipment	250	301
Intangible assets	90,352	91,051
ROU assets	1,337	805
Total assets	115,626	121,880
Trade & other payables	2,275	4,695
Employee provisions (current)	2,927	3,402
Unearned revenue	15,038	14,411
Contingent consideration	-	1,000
Other liabilities	622	931
Current liabilities	20,862	24,439
Employee provisions (non-current)	182	219
Other Provisions / lease liabilities	1,164	733
Deferred tax liabilities	5,617	5,620
Total liabilities	27,825	31,011
Net assets	87,801	90,869

- › \$20.6M cash and no debt as of 30 June 2026
 - › Up \$2.9M vs FY25 (incl. \$1.5M net acquisition payment)
- › Intangibles assets relate mostly to the acquired intangibles from the ExtraMed and Silverlink acquisitions and include provisional balances for the Kyra acquisition in FY26
 - › \$4.0M amortisation in FY26 relates to acquired intangibles
 - › In FY26, Alcidion did not capitalise any R&D expenditure
- › Unearned revenue arises as customers pay in advance of services delivered

Cashflow

High EBITDA to cashflow conversion



Cash flow (\$000)	FY25	FY26	% Change
Receipts from customers	50,858	56,060	10%
Payments to supplier and employees	(45,162)	(49,317)	9%
Net Interest received/finance costs	67	103	54%
Net cash from operating activities	5,763	6,846	19%
Payments for PP&E	(125)	(226)	81%
Acquisition of business	-	(1,475)	NM
Net cash (used) for investing activities	(125)	(1,701)	NM
Payment for principal portion of lease liabilities	(764)	(800)	5%
Net cash (used) from financing activities	(764)	(800)	5%
Cash & cash equivalents opening balance	11,798	17,697	50%
Net (decrease) in cash & cash equivalents	4,874	4,345	(11%)
Effect of exchange rate changes	1,025	(1,400)	NM
Cash & cash equivalents at period end	17,697	20,642	17%

- › Positive operating cashflow of \$6.8M, up 19% on pcp
- › Net consideration payment for Kyra flow acquisition of \$1.5M

04.

Accelerating
customer wins



ALCIDION




Sales momentum accelerating...



\$140m+ of new and renewal TCV won over past 24 months

Average contract term 5-10 years



Notable FY26 New / Expansion Wins



Continued ability to expand functionality with customers over time leading to TCV uplift



Leidos Australia / ADF (AUS)

- › 3rd expansion to the original contract to June 2028, with extension option out to 2036
- › Continues to demonstrate depth and breadth of the Miya Precision platform across a variety of care environments, includes medications management
- › ARR approaching \$6.0M, underpins long-term financial stability of the business



North Cumbria NHS Trust (UK)

- › Expanded to include third-party partner, Mizaic
- › Mizaic (product, MediViewer) to provide electronic document management system (or EDMS)
- › Added non-clinical comms capability in Q3
- › Recent expansions resulted in total TCV of ~\$50.0M over 10 years of contract



Gold Coast Health (AUS)

- › New 5-year contract to provide an end-to-end remote patient monitoring (RPM) solution
- › Initial entry into Gold Coast, a digitally progressive health care organisation
- › First deployment of Miya Precision in Queensland



Hywel Dda + South Tees NHS (UK)

- › Expanded existing relationships via deployment of Miya Emergency (Miya ED) modules
- › Further evidence of land and expand strategy
- › Validates ALC ability to develop and successfully commercialise new modules

Land and Expand Strategy Driving TCV Uplift



Delivering tangible examples of strategy execution...

1 Leidos Australia (Aus)

- › Q2'22 – 6-year contract to deliver Longitudinal Health Record for ADF
- › Q2'23 – Patienttrack and other environments
- › Q2'26 – expanded module capability

2 North Cumbria (UK)

- › Q3'25 – 10-year contract for EPR solution (several Miya modules)
- › Q4'25 – clinical comms module
- › Q1'26 – 3rd party contract w/ Mizaic
- › Q3'26 – non-clinical comms module


3 South Tees (UK)

- › Q2'20 – 5-year contract for several Miya modules
- › Q2'20 – module expansion
- › Q2'23 – extended further 8 yrs with options for additional modules
- › Q3'26 – expanded to include Miya ED

4 Hume (Aus)

- › Q1'25 – New contract covering 15 hospitals across Hume region of Vic, Australia
- › Q4'25 – expanded to include additional hospital sites

Illustrative (TCV) example of progressive module sales; unique ability to accommodate customers budget and requirements



Further EPR Validation: UH Sussex



In May 2026, signed contract with University Hospitals Sussex for new EPR platform solution

Contract Terms



7 years

Minimum
Contract duration



A\$35.0M

Total Contract
Value (TCV)



Potential to add
further modules
over time taking
TCV to \$45m+

EPR Contract - Overview

- Selected following a competitive tender process
- Deploy Miya Precision core modules and Better medications management - provides clinicians real-time access to patient records while streamlining patient flow & improving clinical decision-making
- Deployment commenced in May 2026, expected to run for 18+ months

Traction in UK EPR Market

- 3rd UK EPR contract underpinning our growing referenceability
 - North Cumbria – 10 years, \$45m+ TCV won via competitive tender
 - South Tees - 10 years, \$23m+ TCV with upside for additional modules

UHSussex - Overview



- One of the largest acute trusts in the UK
- Hospital & community care provided across 7 hospitals with more than 1.5 million outpatient appointments, A&E visits and surgery cases

Successful Deployments in FY26



Product Implementation delivery has always been a strength for Alcidion



University Hospitals Southampton (UK)

- › Deployed Miya Emergency – second customer to deploy module and first to replace existing ED digital system
- › During 1st week of operations, UHS saw record patient intake, at one point efficiently managing 200+ concurrent patients in ED
- › Creating more than 5000 documents per day



North Adelaide Local Health Network (AUS)

- › In Q1, 'live' with Miya Flow, Access and Command modules.
- › Electronic journey boards replaced whiteboards across multiple hospitals
- › Bed management and operations centre capabilities 'live' at NALHN Network Operations Centre



Hywel Dda Health Board (UK, Wales)

- › In Q2, went live at Hywel Dda with Miya Flow & Observations and Assessments modules.
- › First site in Wales
- › Success at Hywel Dda positions Alcidion well for further opportunities in this market



North Cumbria NHS Trust (UK)

- › In Q4, completed Phase 1 'go-live' of Miya Precision, an implementation completed on-time culminating in a major digital milestone for the Trust
- › Full implementation progressing throughout FY27
- › Key point of referenceability for new customer procurements

05.

Expanding ALC
position in
patient flow
market



ALCIDION



Patient Flow Market



18% CAGR growth with structural tailwinds across Alcidion's core markets


Overview

- ▶ Global patient flow market growing at 18.1% CAGR to a forecast US\$10.4bn by 2034
 - ▶ UK growing at 18.6% CAGR to US\$588m by 2034
 - ▶ Australia growing at 18.6% CAGR to US\$403M by 2034
- ▶ Alcidion one of the only providers in Australian market with long-standing referenceability + patient flow as a core focus


Growth Drivers

- ▶ Persistent capacity constraints and discharge delays, as hospitals face shortages of staffed beds and delayed diagnostics
- ▶ Healthcare workforce shortages and administrative burden, pushing hospitals toward automated task assignment and AI
- ▶ Need for network wide coordination and operational resilience, driven by multi-hospital systems, virtual hospitals, and regional referral models


GLOBAL MARKET SIZE (US\$M)



CORE MARKETS (US\$M)



NEW MARKET ENTRY (US\$M)



Source: OG Analysis, Patient Flow Management Solutions Market Outlook 2026–2034 (report OGAMVMAD139). All values denoted in USD unless otherwise stated.

Acquisition of Kyra Flow products...



Consolidating Alcidion's leadership position in patient flow market across ANZ



Highly complementary to Alcidion core business



Consolidates market position in ANZ market



Builds recurring revenue whilst being earnings accretive



Future opportunities for Miya Precision & Kyra customers



Attractive acquisition multiple

Strategic Rationale



Customer Expansion

- 33 customers across 5 of 6 states
- Large QLD presence
- Several new VIC customers (private & public)
- Existing relationships with only 2 customers, material increase in Aust. footprint

Patient Flow Leader

- Expands leading position in ANZ & UK flow market
- Strengthens position as a provider of patient flow solutions
- Deep industry & specialist product knowledge
- Infrastructure to ensure seamless customer transition

Long-standing Customer Base

- Average Top 10 customer relationship is ~10 years
- Contracts range 1 - 3 years with the majority on rolling annual contracts
- Embedded & critical software; high barriers to entry

Attractive Financial Profile

- FY26F revenue of ~\$3.6M
- 90%+ recurring revenue
- U'lying EBITDA of \$1.1M
- Negative working capital; cash in advance of services
- Immediately earnings accretive (~2.7x upfront EBITDA multiple)
- Opportunities for Miya Precision & Kyra customers

06.

Growth Strategy and Outlook

Growth Pillars Support a Global Platform



Multi-focus approach combining growth within existing customers, expansion in existing territories and attractive new markets and geographies

Organic Growth

1 Scale Existing Markets

- Continued NHS investment in digital
- EPRs coming up for renewal need to tender
- Expansion into more UK territories
- Expansion of Flow contracts in ANZ (supported by recent successes and Kyra acquisition)
- Increasing opportunities in Virtual Care across ANZ and UK

2 Evolve Product Functionality & Adjacencies

- Deepen AI capabilities across platform data
- Expand further into new modules of care
- Expand product capabilities

3 Expand into New Geographies

Priority Targets / Discussions progressing

- Canada
- Saudi Arabia / UAE
- SE Asia

4

M&A (Buy & Build)

- Expanding market share or product capabilities, ensuring acquisitions are EBITDA accretive (financially disciplined and measured approach to M&A)
- Expand into new geographies
- Expand outside acute / hospital setting

Outlook & Guidance



Growing ARR and contracted implementation underpins EBITDA positive starting position



Outlook

- As of 30 June 2026, contracted & renewal revenue expected to be recognised in FY27 of \$44.9M, up 32% on prior year
 - Includes ARR of \$38.3M ARR + \$6.6M of implementation



FY27 Guidance

- Growth to continue in FY27 with Revenue and Underlying EBITDA to outperform FY26
- Positive outlook underpinned by Alcidion's track record of converting the pipeline into new contracts coupled with the continued demand for modern digital health solutions



07.

Appendix


Miya Precision: An Orchestration layer &/or System of Record




As AI agents are able to execute work autonomously, the SaaS layer is compressed with value shifting to the orchestration and trusted systems of record



Miya Precision as the System of Record




- AI enablement
- Results Management
- Task Management
- Longitudinal Patient Record
- Patient Flow Management
- Virtual Care
- Predictive Analytics




- Clinical Record/CDR
- Patient Administration
- Master Patient Index
- Specialty Specific Systems

Scenario 1




Existing Health IT Solutions

Scenario 2



ersonal use only



ALCIDION